8-K: Silexion Therapeutics Reports Q1 2026 Results, Advances Pancreatic Cancer Trial

Silexion Therapeutics announced first quarter 2026 financial results and provided an update on its Phase 2/3 clinical trial for SIL204 in pancreatic cancer, which has received Israeli Ministry of Health approval and submitted a CTA to Germany.

Summary

• Silexion Therapeutics reported its financial results for the first quarter ended March 31, 2026.
• The company received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial for its lead product candidate, SIL204, for locally advanced pancreatic cancer.
• A Clinical Trial Application (CTA) for the same trial was submitted to Germany via the EU Clinical Trials Information System.
• The Phase 2/3 trial is on track to begin in the second quarter of 2026, involving an initial safety run-in cohort and a subsequent randomized cohort.
• Research and development expenses increased by 133.3% to $1.4 million, driven by toxicology studies and GMP manufacturing for the upcoming trial.
• General and administrative expenses rose by 27.3% to $1.4 million, due to increased professional services and share-based compensation.
• The net loss for the quarter was $2.7 million, an increase of 58.8% from the prior year, primarily due to higher R&D and G&A expenses.
• Cash and cash equivalents decreased to $2.4 million as of March 31, 2026, from $6.0 million at the end of 2025, reflecting operational expenses.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with significant clinical trial progress and successful capital raises to support it, balanced by increasing operational costs and a growing net loss.

Positives

• Received Israeli Ministry of Health approval to initiate Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer.
• Submitted Clinical Trial Application (CTA) to Germany for the Phase 2/3 trial of SIL204.
• Phase 2/3 trial initiation remains on track for the second quarter of 2026.
• Strengthened balance sheet through a May 2026 warrant exercise inducement transaction, raising approximately $1.0 million in gross proceeds.
• Additional capital raised under the at-the-market facility.
• Obtained shareholder approval for a prospective reverse share split.
• Believes restored compliance with Nasdaq Capital Market continued listing requirements due to increased shareholders' equity from recent financing activities.

Negatives

• Net loss for the first quarter of 2026 increased by 58.8% to $2.7 million compared to $1.7 million in the same period of 2025.
• Research and development expenses increased by 133.3% to $1.4 million.
• General and administrative expenses increased by 27.3% to $1.4 million.
• Cash and cash equivalents decreased significantly from $6.0 million at December 31, 2025, to $2.4 million at March 31, 2026.

Risks

• The company's ability to initiate and conduct clinical trials, including the Phase 2/3 trial of SIL204.
• Whether Silexion's strategy, future operations, financial position, projected costs, prospects, and plans will run as currently anticipated.
• The impact of the regulatory environment and compliance complexities.
• Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital.
• Whether Silexion can maintain its Nasdaq listing, including its ability to continue to satisfy the Nasdaq shareholders' equity and minimum bid price requirements.
• Potential for delays in clinical trial initiation or regulatory approvals.
• The effectiveness and safety of SIL204 in treating locally advanced pancreatic cancer.

Future Outlook

The company is on track to initiate its Phase 2/3 clinical trial for SIL204 in the second quarter of 2026. They are continuing to evaluate financing alternatives to support the advancement of SIL204 into the clinic. The company believes it has restored compliance with Nasdaq listing requirements and aims to maintain it.

Management Comments

• "The first quarter and the period since represented a defining moment in Silexion's evolution. With the Israeli Ministry of Health approval to initiate our Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, and our subsequent submission of a Clinical Trial Application to Germany under the EU Clinical Trials Regulation, we have advanced SIL204 from a preclinical asset into clinical-stage development across two major regulatory jurisdictions."
• "We remain on track to initiate the Phase 2/3 clinical trial in the second quarter of 2026, with the goal of bringing an RNAi-based approach to patients with KRAS-driven cancers who have limited treatment options today."
• "During the first quarter and subsequent to quarter end, we executed a series of capital-raising and corporate actions designed to support our clinical development plan and our continued Nasdaq listing."
• "We continue to evaluate financing alternatives as we work to support the advancement of SIL204 into the clinic in the second quarter of 2026."

Industry Context

StockSavvy.ai notes that Silexion Therapeutics is operating in the highly competitive and capital-intensive oncology drug development sector, specifically focusing on KRAS-driven cancers, a significant area of unmet medical need. The advancement of SIL204 into Phase 2/3 trials and securing regulatory approvals in key jurisdictions like Israel and Germany are critical steps for a clinical-stage biotech company aiming to validate its platform and therapeutic candidates.

Corporate Governance

Related Party Transactions

• Includes amounts due to related party for private warrants to purchase ordinary shares.
• Includes a Related Party Promissory Note of $1,553 thousand as a current liability and $1,568 thousand as a non-current liability.
• Research and development expenses included $130 thousand from related parties for the three-month period ended March 31, 2026.
• General and administrative expenses included $215 thousand from related parties for the three-month period ended March 31, 2026.
• Financial expense (income), net included $(15) thousand from related parties for the three-month period ended March 31, 2026.

Stakeholder Impact

• Shareholders: Recent financing activities and warrant exercises have strengthened equity, potentially restoring Nasdaq compliance, but increased net loss and R&D spending may impact future value.
• Employees: Increased share-based compensation expenses noted, indicating potential equity incentives for key personnel.
• Creditors: The company's cash position has decreased, and reliance on future financing is noted, which could impact its ability to meet obligations if capital is not secured.
• Regulatory Bodies: Progress in clinical trial applications and approvals is a key factor for regulatory oversight.

Next Steps

• Initiate the Phase 2/3 clinical trial of SIL204 in the second quarter of 2026.
• Conduct the initial safety run-in cohort of approximately 18 patients.
• Expand into a randomized cohort of approximately 166 patients.
• Continue to evaluate financing alternatives.
• Maintain compliance with Nasdaq Capital Market continued listing requirements.

Key Dates

Recommendation

The company is making significant progress in its clinical development with regulatory approvals and trial initiations, which is positive. However, the increasing net loss, decreasing cash reserves, and the inherent risks of clinical-stage biotech development warrant a cautious 'hold' recommendation until further clinical data and sustained financial stability are demonstrated.

Keywords

Silexion Therapeutics, SIL204, Pancreatic Cancer, RNAi Therapy, Clinical Trial, Biotechnology, KRAS-driven Cancers, SEC Filing